A Comprehensive Analysis On The Association Between The KI 67 And P 53 Markers And Different Types Of Brain Tumors

Abstract

Gliomas are characterized by mutations in the p53 tumor suppressor gene. The cell proliferation marker Ki-67 is frequently employed in the context of gliomas. The survival rates of individuals with brain tumors exhibit considerable variation, with treatment trials heavily relying on prognostic markers. The utilization of digital pathology and improved immune-histochemical diagnostics allowed for a more accurate assessment of the true significance of the Ki-67 labeling index (LIpredictive) in glioblastomas by eliminating the presence of proliferating non-tumor cells during research. Among these markers, MIB1 (Ki67) stands out as the most popular and practical option. Consequently, the Ki-67 Labeling Index (LI) may possess prognostic and therapeutic implications for patients. The p53 tumor gene (TP53) is the gene that is not frequently altered in various malignancies and is also absent in a variety of different types of brain tumors. The identification of the molecular mechanisms through which p53 mutations cause cancer forms the basis for the development of new treatment strategies. Obtaining more conclusive results could be facilitated by reviewing studies that involve a larger number of patients across multiple centers and have a planned prospective follow-up of longer duration. In future research, it might be feasible to explore whether the incorporation of surgical, histological, and imaging indications could result in a more accurate method for predicting recurrence.